The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis

Ignacio Dolado, Aneta Swat, Nuria Ajenjo et al. · Cancer Cell · 2007 · 396 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +14

Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

Xin‐Yan Pei, Yun Dai, Steven Grant · Clinical Cancer Research · 2004 · 381 citations

Medicine, Oncology, Pharmacology +17

Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia

Tomas Vilimas, Joaquina Mascarenhas, Teresa Palomero et al. · Nature Medicine · 2006 · 333 citations

Life Sciences, Molecular Biology, Oncology +12

Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Pier Luigi Zinzani, Gerardo Musuraca, Monica Tani et al. · Journal of Clinical Oncology · 2007 · 280 citations · Full text

Medicine, Oncology, Pharmacology +17